Financial reports
10-K
2023 FY
Annual report
25 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
10 May 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
30 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
25 Mar 24
8-K
Volition appoints Dr Andrew Retter as Chief Medical Officer
19 Mar 24
8-K
Other Events
2 Jan 24
8-K
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre
5 Dec 23
8-K
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update
14 Nov 23
8-K
VolitionRx Limited Announces Second Quarter 2023 Financial
14 Aug 23
8-K
Departure of Directors or Certain Officers
30 Jun 23
8-K
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock
2 Jun 23
8-K
VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update
10 May 23
8-K
VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update
15 Mar 23
Registration and prospectus
D
$100.00 k in equity, sold $100.00 k, 1 investor
26 Mar 24
S-8
Registration of securities for employees
14 Jul 23
424B5
Prospectus supplement for primary offering
2 Jun 23
424B5
Prospectus supplement for primary offering
31 May 23
424B5
Prospectus supplement for primary offering
21 Feb 23
424B5
Prospectus supplement for primary offering
16 Feb 23
S-8
Registration of securities for employees
30 Sep 22
424B5
Prospectus supplement for primary offering
1 Aug 22
424B5
Prospectus supplement for primary offering
28 Jul 22
424B5
Prospectus supplement for primary offering
20 May 22
Proxies
DEF 14A
Definitive proxy
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 22
DEF 14A
Definitive proxy
29 Apr 21
PRE 14A
Preliminary proxy
2 Apr 21
DEFA14A
Additional proxy soliciting materials
17 Jun 20
DEF 14A
Definitive proxy
29 Apr 20
PRE 14A
Preliminary proxy
1 Apr 20
DEF 14A
Definitive proxy
29 Apr 19
PRE 14A
Preliminary proxy
29 Mar 19
DEF 14A
Definitive proxy
20 Jul 18
Other
UPLOAD
Letter from SEC
3 Jan 24
CORRESP
Correspondence with SEC
20 Dec 23
UPLOAD
Letter from SEC
15 Dec 23
EFFECT
Notice of effectiveness
9 Nov 21
CORRESP
Correspondence with SEC
4 Nov 21
UPLOAD
Letter from SEC
30 Sep 21
EFFECT
Notice of effectiveness
18 Feb 20
CORRESP
Correspondence with SEC
13 Feb 20
CORRESP
Correspondence with SEC
13 Feb 20
UPLOAD
Letter from SEC
13 Feb 20
Ownership
3
Andrew Retter
22 Mar 24
SC 13G/A
Lagoda Investment Management, L.P.
14 Feb 24
SC 13D/A
Reynolds Cameron John
9 Feb 24
4
Gael Forterre
26 Jan 24
4
Gaetan Michel
26 Jan 24
4
Guy Archibald Innes
26 Jan 24
4
Jacob Vincent Micallef
26 Jan 24
4
Jasmine Kway
26 Jan 24
4
Kim Nguyen
26 Jan 24
4
Martin Charles Faulkes
26 Jan 24